TABLE II.
Key model parameters and alternative values for the sensitivity analyses
| Parameter | Base case | Sensitivity analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||
| Year 1 | Year 2 | Year 3 | Lower | Upper | |||||
|
|
|
||||||||
| Year 1 | Year 2 | Year 3 | Year 1 | Year 2 | Year 3 | ||||
| Eligible patients (n)a | 3359 | 3393 | 3427 | 2687 | 2714 | 2742 | 4031 | 4072 | 4112 |
|
| |||||||||
| Market capture for SC rituximab (%) | 50 | 58 | 62 | 50 | 50 | 50 | 90 | 95 | 100 |
|
| |||||||||
| Patients with drug wastage (%) | 10 | 0 | 20 | ||||||
|
| |||||||||
| Costs (CA$, 2017) | |||||||||
| IV 100 mg format | 471 | 453 | 489 | ||||||
| IV 500 mg format | 2353 | 2266 | 2447 | ||||||
| Systemic therapy suite hour | 199 | 159 | 239 | ||||||
|
| |||||||||
| Savings per administration | |||||||||
| Systemic therapy suite time (minutes) | 199 | 159 | 238 | ||||||
|
| |||||||||
| Cycles (n) | |||||||||
| Induction therapy | 6 | 4 | 8 | ||||||
| Maintenance therapy | 7 | 4 | 8 | ||||||
|
| |||||||||
| Patients with FL receiving maintenance (%) | 75 | 60 | 90 | ||||||
a
Includes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).